ACT-1004-1239

• CAT Number: I021330
• CAS Number: 2178049-58-4
• Molecular Formula: C27H28F2N6O3
• Molecular Weight: 522.55
• Purity: ≥95%
• Synonyms: N-[(3S,4S)-1-(cyclopropylmethyl)-3-[(1-pyrimidin-2-ylcyclopropyl)carbamoyl]piperidin-4-yl]-5-(2,4-difluorophenyl)-1,2-oxazole-3-carboxamide
• InChI: InChI=1S/C27H28F2N6O3/c28-17-4-5-18(20(29)12-17)23-13-22(34-38-23)25(37)32-21-6-11-35(14-16-2-3-16)15-19(21)24(36)33-27(7-8-27)26-30-9-1-10-31-26/h1,4-5,9-10,12-13,16,19,21H,2-3,6-8,11,14-15H2,(H,32,37)(H,33,36)/t19-,21-/m0/s1
• InChIKey: IIDSHAJKXPUYSL-FPOVZHCZSA-N
• SMILES: C1CN(C[C@@H]([C@H]1NC(=O)C2=NOC(=C2)C3=C(C=C(C=C3)F)F)C(=O)NC4(CC4)C5=NC=CC=N5)CC6CC6

ACT-1004-1239（Cat No.:I021330）is a potent, selective antagonist of the C-C chemokine receptor 7 (CCR7), a G protein–coupled receptor crucial for immune cell trafficking, lymph node homing, and adaptive immune responses. By blocking CCR7 signaling, ACT-1004-1239 disrupts chemokine-mediated migration of T cells and dendritic cells, modulating immune activation and inflammatory processes. It is a valuable research tool for studying CCR7’s role in immunity, cancer metastasis, and autoimmune disorders. ACT-1004-1239 holds therapeutic potential for treating inflammatory diseases, immunological imbalances, and cancers where CCR7-driven cell migration contributes to disease progression.